BioCentury | Apr 26, 2019
Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

...MAS receptor agonists in development for other indications. MorphoSys AG and Tarix Orphan LLC have TXA127...
BioCentury | Feb 11, 2019
Distillery Therapeutics

Neurology

...vascular dementia, mixed dementia and traumatic brain injury. MorphoSys AG and Tarix Orphan LLC have TXA127...
BioCentury | Jan 25, 2018
Translation in Brief

No TNFα for transplants

...in development for multiple indications, but none for stem cell engraftment. Tarix Orphan LLC has TXA127...
BioCentury | Jan 27, 2017
Clinical News

TXA127 regulatory update

...rare pediatric disease designation to TXA127 from Tarix to treat recessive dystrophic epidermolysis bullosa (RDEB). TXA127...
...and is in preclinical testing. Tarix Orphan LLC , Cambridge, Mass. Product: TXA127 Business: Dermatology Nora Weintraub TXA127 Tarix...
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...miR-155) antagonist Preclinical Regenesance B.V. Regenemab mAb against complement 6 (C6) Preclinical Tarix Orphan LLC TXA127...
BioCentury | Oct 19, 2015
Clinical News

TXA127 regulatory update

...FDA granted Fast Track designation to TXA127 from Tarix Orphan to reduce skeletal muscle damage and...
...a Phase II trial of the formulation of the angiotensin (1-7) peptide to treat DMD. TXA127...
...purchased TXA127 from Tarix Pharmaceuticals Ltd. (Brookline, Mass.). Tarix Orphan LLC , Cambridge, Mass. Product: TXA127...
BioCentury | Mar 18, 2013
Clinical News

Tarix preclinical data

...In a rat model of ischemic stroke, TXA127 significantly improved neurologic score, forelimb placement, stepping test...
...score, forelimb placement, stepping test and body swing test scores vs. undisclosed controls. Tarix said TXA127...
...stroke, with positive improvements detectable within 2 weeks and continuing throughout the 7-week study. Additionally, TXA127...
BioCentury | Dec 3, 2012
Company News

Tarix, Unigene deal

...Tarix and Unigene partnered to develop an oral formulation of Tarix's TXA127 using Unigene's Peptelligence drug...
...angiotensin I-VII and its functional equivalents, analogs and derivatives. Angiotensin is the pharmaceutical ingredient in TXA127...
...upfront and milestone payments, and royalties from a third-party licensing deal (see BioCentury, Sept. 24). TXA127...
BioCentury | Sep 24, 2012
Company News

Tarix, Unigene deal

...I-VII and its functional equivalents, analogs and derivatives. Angiotensin is the pharmaceutical ingredient in Tarix's TXA127...
...in February when the partners entered a feasibility deal to evaluate an oral formulation of TXA127...
...milestone payments, and royalties from a third-party licensing deal. The companies declined to disclose details. TXA127...
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

...funding, milestones and royalties Pfizer Inc. (NYSE:PFE) Jan-2010 Lanthio Pharma B.V. Exclusive, worldwide rights to lanthionine-Ang(1-7) peptide...
...autoimmune/inflammatory diseases 2004 $38.5M Lanthio Pharma B.V. Lanthionine constrained peptides produced in Lactococcus lactis Preclin lanthionine-Ang(1-7) peptide...
Items per page:
1 - 10 of 16